View Item 

Show simple item record

Systemic Sclerosis–Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration–Approved Therapies in Clinical Practice
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorLescoat, Alain
dc.contributor.authorRoofeh, David
dc.contributor.authorBernstein, Elana J.
dc.contributor.authorKazerooni, Ella A.
dc.contributor.authorRoth, Michael D.
dc.contributor.authorMartinez, Fernando
dc.contributor.authorFlaherty, Kevin R.
dc.contributor.authorDenton, Christopher P.
dc.date.accessioned2022-01-06T15:49:44Z
dc.date.available2023-02-06 10:49:43en
dc.date.available2022-01-06T15:49:44Z
dc.date.issued2022-01
dc.identifier.citationKhanna, Dinesh; Lescoat, Alain; Roofeh, David; Bernstein, Elana J.; Kazerooni, Ella A.; Roth, Michael D.; Martinez, Fernando; Flaherty, Kevin R.; Denton, Christopher P. (2022). "Systemic Sclerosis–Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration–Approved Therapies in Clinical Practice." Arthritis & Rheumatology 74(1): 13-27.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/171184
dc.publisherWiley Periodicals, Inc.
dc.publisherLittle Brown & Co
dc.titleSystemic Sclerosis–Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration–Approved Therapies in Clinical Practice
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171184/1/art41933_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171184/2/art41933.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171184/3/art41933-sup-0001-Disclosureform.pdf
dc.identifier.doi10.1002/art.41933
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceKhanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator‐initiated, multicenter, double‐blind, randomized, placebo‐controlled trial. Arthritis Rheumatol 2020; 72: 125 – 36.
dc.identifier.citedreferenceChung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, et al. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open‐label extension of a phase 2, double‐blind randomised trial. Lancet Rheumatol 2020; 2: e743 – 53.
dc.identifier.citedreferenceSircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 2018; 57: 2106 – 13.
dc.identifier.citedreferenceEbata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double‐blind, investigator‐initiated, randomised, placebo‐controlled trial. Lancet Rheumatol 2021; 3: E489 – 97.
dc.identifier.citedreferenceSullivan KM, Goldmuntz EA, Keyes‐Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem‐cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 35 – 47.
dc.identifier.citedreferenceLaunay D, Marjanovic Z, de Bazelaire C, Florea L, Zohar S, Keshtmand H, et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. J Rheumatol 2009; 36: 1460 – 3.
dc.identifier.citedreferenceRoofeh D, Lescoat A, Khanna D. Treatment for systemic sclerosis‐associated interstitial lung disease. Curr Opin Rheumatol 2021; 33: 240 – 8.
dc.identifier.citedreferenceBernstein EJ, Peterson ER, Sell JL, D’Ovidio F, Arcasoy SM, Bathon JM, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol 2015; 67: 1314 – 22.
dc.identifier.citedreferenceWeill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34: 1 – 15.
dc.identifier.citedreferenceJablonski R, Dematte J, Bhorade S. Lung transplantation in scleroderma: recent advances and lessons [review]. Curr Opin Rheumatol 2018; 30: 562 – 9.
dc.identifier.citedreferenceQuanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi‐ethnic reference values for spirometry for the 3–95‐yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324 – 43.
dc.identifier.citedreferenceKhanna D, Denton CP. Integrating new therapies for systemic sclerosis‐associated lung fibrosis in clinical practice. Lancet Respir Med 2021; 9: 560 – 2.
dc.identifier.citedreferenceDowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax 2017; 72: 610 – 9.
dc.identifier.citedreferenceNakayama K, Nakajima Y, Tanaka R, Hirata KI, Emoto N. Predictors of long‐term outcomes in patients with connective tissue disease associated with pulmonary arterial hypertension. J Clin Rheumatol 2020. doi: https://doi.org/10.1097/RHU.0000000000001447. E‐pub ahead of print.
dc.identifier.citedreferenceKanjrawi AA, Mathers L, Webster S, Corte TJ, Carey S. Nutritional status and quality of life in interstitial lung disease: a prospective cohort study. BMC Pulm Med 2021; 21: 51.
dc.identifier.citedreferenceJouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res 2020; 21: 312.
dc.identifier.citedreferenceSuleman Y, Clark KE, Cole AR, Ong VH, Denton CP. Real‐world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti‐topoisomerase‐positive patients. Rheumatology (Oxford) 2021; 60: 3945 – 6.
dc.identifier.citedreferenceKhanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH. Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Making 2008; 28: 926 – 37.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes‐Elstein L, et al. Short‐term progression of interstitial lung disease in systemic sclerosis predicts long‐term survival in two independent clinical trial cohorts. Ann Rheum Dis 2019; 78: 122 – 30.
dc.identifier.citedreferenceLajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta‐analysis [review]. Lancet Respir Med 2016; 4: 291 – 305.
dc.identifier.citedreferenceKhanna D, Zhao C, Saggar R, Mathai SC, Chung L, Coghlan JG, et al. Long‐term outcomes in patients with connective tissue disease–associated pulmonary arterial hypertension in the modern treatment era: meta‐analyses of randomized, controlled trials and observational registries. Arthritis Rheumatol 2021; 73: 837 – 47.
dc.identifier.citedreferenceChandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Interleukin‐6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial. Am J Transplant 2020; 21: 2543 – 54.
dc.identifier.citedreferenceKhanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al. An open‐label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma‐associated interstitial lung disease: the LOTUSS trial. J Rheumatol 2016; 43: 1672 – 9.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, LeClair H, Roth MD, Kim G, Goldin J, et al. Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient‐reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II. ACR Open Rheumatol 2020; 2: 362 – 70.
dc.identifier.citedreferenceDenton CP, Khanna D. Systemic sclerosis [review]. Lancet 2017; 390: 1685 – 99.
dc.identifier.citedreferenceFrantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum 2016; 46: 115 – 23.
dc.identifier.citedreferenceLeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202 – 5.
dc.identifier.citedreferenceLeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis [review]. J Rheumatol 2001; 28: 1573 – 6.
dc.identifier.citedreferenceDomsic RT, Medsger TA. Autoantibodies and their role in scleroderma clinical care. Curr Treatm Opt Rheumatol 2016; 2: 239 – 51.
dc.identifier.citedreferenceNihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett‐Smith EC, Fonseca C, et al. Using autoantibodies and cutaneous subset to develop outcome‐based disease classification in systemic sclerosis. Arthritis Rheumatol 2020; 72: 465 – 76.
dc.identifier.citedreferenceCoghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence‐based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340 – 9.
dc.identifier.citedreferenceChan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp‐2 cell patterns 2014–2015 [review]. Front Immunol 2015; 6: 412.
dc.identifier.citedreferenceKhanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020; 201: 650 – 60.
dc.identifier.citedreferenceElhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir‐Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897 – 905.
dc.identifier.citedreferenceMeyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007; 34: 104 – 9.
dc.identifier.citedreferenceBernstein EJ, Jaafar S, Assassi S, Domsic RT, Frech TM, Gordon JK, et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2020; 72: 1892 – 6.
dc.identifier.citedreferenceHoffmann‐Vold AM, Molberg Ø, Midtvedt Ø, Garen T, Gran JT. Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 2013; 40: 1127 – 33.
dc.identifier.citedreferenceDougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, et al. The Scleroderma Patient‐Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford) 2018; 57: 1623 – 31.
dc.identifier.citedreferenceRoofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials. J Scleroderma Relat Disord 2020; 5: 61 – 71.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma‐related interstitial lung disease (SLS II): a randomised controlled, double‐blind, parallel group trial. Lancet Respir Med 2016; 4: 708 – 19.
dc.identifier.citedreferenceDistler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med 2019; 380: 2518 – 28.
dc.identifier.citedreferenceFlaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SL, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718 – 27.
dc.identifier.citedreferenceKhanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387: 2630 – 40.
dc.identifier.citedreferenceKhanna D, Lin CJ, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Respir Med 2020; 8: 963 – 74.
dc.identifier.citedreferenceRoofeh D, Lin CJ, Goldin J, Kim GH, Furst DE, Denton CP, et al. Tocilizumab prevents progression of early systemic sclerosis–associated interstitial lung disease. Arthritis Rheumatol 2021; 73: 1301 – 10.
dc.identifier.citedreferenceHoffmann‐Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Distler O. Assessment of recent evidence for the management of patients with systemic sclerosis‐associated interstitial lung disease: a systematic review. ERJ Open Res 2021; 7: 00235 – 2020.
dc.identifier.citedreferenceVolkmann ER, Varga J. Emerging targets of disease‐modifying therapy for systemic sclerosis [review]. Nat Rev Rheumatol 2019; 15: 208 – 24.
dc.identifier.citedreferenceLescoat A, Ballerie A, Augagneur Y, Morzadec C, Vernhet L, Fardel O, et al. Distinct properties of human M‐CSF and GM‐CSF monocyte‐derived macrophages to simulate pathological lung conditions in vitro: application to systemic and inflammatory disorders with pulmonary involvement. Int J Mol Sci 2018; 19: 894.
dc.identifier.citedreferenceLescoat A, Ballerie A, Jouneau S, Fardel O, Vernhet L, Jego P, et al. M1/M2 polarisation state of M‐CSF blood‐derived macrophages in systemic sclerosis [editorial]. Ann Rheum Dis 2019; 78: e127.
dc.identifier.citedreferenceValenzi E, Bulik M, Tabib T, Morse C, Sembrat J, Bittar HT, et al. Single‐cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis‐associated interstitial lung disease. Ann Rheum Dis 2019; 78: 1379 – 87.
dc.identifier.citedreferenceWollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis [review]. Eur Respir J 2015; 45: 1434 – 45.
dc.identifier.citedreferenceDenton CP, Ong VH, Xu S, Chen‐Harris H, Modrusan Z, Lafyatis R, et al. Therapeutic interleukin‐6 blockade reverses transforming growth factor‐β pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 2018; 77: 1362 – 71.
dc.identifier.citedreferenceNumajiri H, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki‐Ogawa A, Asano Y, et al. B cell depletion inhibits fibrosis via suppressing pro‐fibrotic macrophage differentiation in a mouse model of systemic sclerosis. Arthritis Rheumatol 2021 doi: https://doi.org/10.1002/art.41798. E‐pub ahead of print.
dc.identifier.citedreferenceMauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling by IL‐6 promotes alternative activation of macrophages to limit endotoxemia and obesity‐associated resistance to insulin. Nat Immunol 2014; 15: 423 – 30.
dc.identifier.citedreferenceGao X, Jia G, Guttman A, DePianto DJ, Morshead KB, Sun KH, et al. Osteopontin links myeloid activation and disease progression in systemic sclerosis. Cell Rep Med 2020; 1: 100140.
dc.identifier.citedreferencePetrova DT, Brandhorst G, Koch C, Schultze FC, Eberle C, Walson PD, et al. Mycophenolic acid reverses TGF β‐induced cell motility, collagen matrix contraction and cell morphology in vitro. Cell Biochem Funct 2015; 33: 503 – 8.
dc.identifier.citedreferenceAllison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action [review]. Immunopharmacology 2000; 47: 85 – 118.
dc.identifier.citedreferenceHoffmann‐Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence‐based European consensus statements. Lancet Rheumatol 2020; 2: e71 – 83.
dc.identifier.citedreferenceRoofeh D, Jaafar S, Vummidi D, Khanna D. Management of systemic sclerosis‐associated interstitial lung disease [review]. Curr Opin Rheumatol 2019; 31: 241 – 9.
dc.identifier.citedreferenceFischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976 – 87.
dc.identifier.citedreferenceRaghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence‐based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788 – 824.
dc.identifier.citedreferenceRemy‐Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A. Importance of ground‐glass attenuation in chronic diffuse infiltrative lung disease: pathologic‐CT correlation. Radiology 1993; 189: 693 – 8.
dc.identifier.citedreferenceTakei R, Arita M, Kumagai S, Ito Y, Tokioka F, Koyama T, et al. Radiographic fibrosis score predicts survival in systemic sclerosis‐associated interstitial lung disease. Respirology 2018; 23: 385 – 91.
dc.identifier.citedreferenceBouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581 – 6.
dc.identifier.citedreferenceRaghu G, Remy‐Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44 – 68.
dc.identifier.citedreferenceKim HG, Tashkin DP, Clements PJ, Li G, Brown MS, Elashoff R, et al. A computer‐aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 2010; 28: S26 – 35.
dc.identifier.citedreferenceGoldin JG, Kim GH, Tseng CH, Volkmann E, Furst D, Clements P, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc 2018; 15: 1286 – 95.
dc.identifier.citedreferenceGoh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248 – 54.
dc.identifier.citedreferenceWinstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma‐associated interstitial lung disease: a systematic review. Chest 2014; 146: 422 – 36.
dc.identifier.citedreferenceSuliman YA, Dobrota R, Huscher D, Nguyen‐Kim TD, Maurer B, Jordan S, et al. Pulmonary function tests: high rate of false‐negative results in the early detection and screening of scleroderma‐related interstitial lung disease. Arthritis Rheumatol 2015; 67: 3256 – 61.
dc.identifier.citedreferenceHolland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease [review]. Eur Respir J 2014; 44: 1428 – 46.
dc.identifier.citedreferenceAmerican Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six‐minute walk test. Am J Respir Crit Care Med 2002; 166: 111 – 17.
dc.identifier.citedreferenceThe Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little Brown & Co; 1994: 253 – 6.
dc.identifier.citedreferenceMahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580 – 6.
dc.identifier.citedreferenceDistler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease [review]. Eur Respir J 2020; 55: 1902026.
dc.identifier.citedreferenceLiu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, et al. Does C‐reactive protein predict the long‐term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013; 65: 1375 – 80.
dc.identifier.citedreferenceNihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long‐term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625 – 35.
dc.identifier.citedreferenceStock CJ, Hoyles RK, Daccord C, Kokosi M, Visca D, De Lauretis A, et al. Serum markers of pulmonary epithelial damage in systemic sclerosis‐associated interstitial lung disease and disease progression. Respirology 2021; 26: 461 – 8.
dc.identifier.citedreferenceSalazar GA, Kuwana M, Wu M, Estrada‐Y‐Martin RM, Ying J, Charles J, et al. KL‐6 but not CCL‐18 is a predictor of early progression in systemic sclerosis‐related interstitial lung disease. J Rheumatol 2018; 45: 1153 – 8.
dc.identifier.citedreferenceJaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, et al. Smoking in systemic sclerosis: a longitudinal European Scleroderma Trials and Research group study. Arthritis Rheumatol 2018; 70: 1829 – 34.
dc.identifier.citedreferenceRoofeh D, Khanna D. Management of systemic sclerosis: the first five years [review]. Curr Opin Rheumatol 2020; 32: 228 – 37.
dc.identifier.citedreferenceYoung A, Moles VM, Jaafar S, Visovatti S, Huang S, Vummidi D, et al. Performance of the DETECT algorithm for pulmonary hypertension screening in a systemic sclerosis cohort. Arthritis Rheumatol 2021; 73: 1731 – 7.
dc.identifier.citedreferenceKim GH, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, et al. Using transitional changes on high‐resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis–related interstitial lung disease. Arthritis Rheumatol 2020; 72: 316 – 25.
dc.identifier.citedreferenceNamas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo‐controlled trials. Arthritis Care Res (Hoboken) 2018; 70: 439 – 44.
dc.identifier.citedreferenceJaafar S, Lescoat A, Huang S, Gordon J, Hinchcliff M, Shah AA, et al. Clinical characteristics, visceral involvement, and mortality in at‐risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther 2021; 23: 170.
dc.identifier.citedreferenceHighland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis‐associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 2021; 9: 96 – 106.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41933_am.pdf
Size:
464.8KB
Format:
PDF
View/Open
Name:
art41933.pdf
Size:
1.007MB
Format:
PDF
View/Open
Name:
art41933-sup-0001-Disclosurefo ...
Size:
398.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.